Clinical Trial Update: Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating tafasitamab plus lenalidomide for relapsed central nervous system lymphomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)
• Revlimid (lenalidomide)

Snippet

Sponsor: James Rubenstein | Conditions: CNS Lymphoma, Primary Central Nervous System Lymphoma | Phase 1, Phase 2 | Status: RECRUITING